| Treatment for brain metastases: ASCO-SNO-ASTRO guideline MA Vogelbaum, PD Brown, H Messersmith, PK Brastianos, S Burri, ... Neuro-oncology 24 (3), 331-357, 2022 | 335 | 2022 |
| A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients SF Hussain, LY Kong, J Jordan, C Conrad, T Madden, I Fokt, W Priebe, ... Cancer research 67 (20), 9630-9636, 2007 | 333 | 2007 |
| Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy JT Jordan, W Sun, SF Hussain, G DeAngulo, SS Prabhu, AB Heimberger Cancer Immunology, Immunotherapy 57, 123-131, 2008 | 262 | 2008 |
| Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells P Karschnia, JT Jordan, DA Forst, IC Arrillaga-Romany, TT Batchelor, ... Blood, The Journal of the American Society of Hematology 133 (20), 2212-2221, 2019 | 248 | 2019 |
| Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma L Nayak, AM Molinaro, K Peters, JL Clarke, JT Jordan, J de Groot, ... Clinical Cancer Research 27 (4), 1048-1057, 2021 | 167 | 2021 |
| Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies KM Field, JT Jordan, PY Wen, MA Rosenthal, DA Reardon Cancer 121 (7), 997-1007, 2015 | 90 | 2015 |
| Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation SR Plotkin, L Messiaen, E Legius, P Pancza, RA Avery, JO Blakeley, ... Genetics in Medicine 24 (9), 1967-1977, 2022 | 85 | 2022 |
| Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype–phenotype correlation M Koczkowska, T Callens, A Gomes, A Sharp, Y Chen, AD Hicks, ... Genetics in Medicine 21 (4), 867-876, 2019 | 82 | 2019 |
| Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial MJ Frigault, J Dietrich, K Gallagher, M Roschewski, JT Jordan, D Forst, ... Blood, The Journal of the American Society of Hematology 139 (15), 2306-2315, 2022 | 79 | 2022 |
| Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis S Ahlawat, LM Fayad, MS Khan, MA Bredella, GJ Harris, DG Evans, ... Neurology 87 (7_Supplement_1), S31-S39, 2016 | 74 | 2016 |
| Increased risk of cerebrovascular disease among patients with neurofibromatosis type 1: population-based approach AR Terry, JT Jordan, L Schwamm, SR Plotkin Stroke 47 (1), 60-65, 2016 | 70 | 2016 |
| The use of MEK inhibitors in neurofibromatosis type 1–associated tumors and management of toxicities LJ Klesse, JT Jordan, HB Radtke, T Rosser, E Schorry, N Ullrich, ... The oncologist 25 (7), e1109-e1116, 2020 | 65 | 2020 |
| Glioblastoma care in the elderly JT Jordan, ER Gerstner, TT Batchelor, DP Cahill, SR Plotkin Cancer 122 (2), 189-197, 2016 | 64 | 2016 |
| Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. DA Reardon, L Nayak, KB Peters, JL Clarke, JT Jordan, JF De Groot, ... Journal of Clinical Oncology 36 (15_suppl), 2006-2006, 2018 | 63 | 2018 |
| Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations JC DeWitt, JT Jordan, MP Frosch, WR Samore, AJ Iafrate, DN Louis, ... Neuro-oncology 19 (12), 1640-1650, 2017 | 59 | 2017 |
| A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas RL Beauchamp, MF James, PA DeSouza, V Wagh, WN Zhao, JT Jordan, ... Oncotarget 6 (19), 16981, 2015 | 55 | 2015 |
| Successful anti‐CD19 CAR T‐cell therapy in HIV‐infected patients with refractory high‐grade B‐cell lymphoma JS Abramson, KE Irwin, MJ Frigault, J Dietrich, B McGree, JT Jordan, ... Cancer 125 (21), 3692-3698, 2019 | 50 | 2019 |
| Genotype-targeted local therapy of glioma GM Shankar, AR Kirtane, JJ Miller, H Mazdiyasni, J Rogner, T Tai, ... Proceedings of the National Academy of Sciences 115 (36), E8388-E8394, 2018 | 50 | 2018 |
| Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials PL Wolters, S Martin, VL Merker, JH Tonsgard, SE Solomon, A Baldwin, ... Neurology 87 (7_Supplement_1), S4-S12, 2016 | 50 | 2016 |
| Characteristics of graduating US allopathic medical students pursuing a career in neurology L Gutmann, C Cahill, JT Jordan, CE Gamaldo, V Santini, I Ali, M Soni, ... Neurology 92 (17), e2051-e2063, 2019 | 39 | 2019 |
